IBA Proton Therapy

Startpagina
België
Louvain-la-Neuve
IBA Proton Therapy

IBA, Proton Therapy Unlimited! Want to get an insider view on how proton therapy develops worldwide?Go behind the scene with us.

The information shared on this Social Media channel is intended solely for the use of healthcare professionals.

30/10/2025

🌸🎗 “It’s a huge trial. 1,239 patients is the largest randomized proton versus photon trial. We’re very grateful to the patients that trusted us with their care and were willing to enroll on this trial to help other patients and help further research.”

As we conclude our Breast Cancer Awareness Month series, Dr. Shannon MacDonald, the clinical chair of RadComp and medical director of the Southwest Florida Proton Center, reflects on the impact of this trial. Progress in cancer care is only possible thanks to the patients, clinicians, and researchers who make it happen.

S.M. MacDonald & Al. - Phase III randomized trial of proton vs. photon therapy for patients with non-metastatic breast cancer receiving comprehensive nodal radiation: A radiotherapy comparative effectiveness (RadComp) Consortium Trial: Health-related quality of life outcomes - ASTRO2025).

👉 Watch the full series on our YouTube channel to see how proton therapy is advancing breast cancer treatment: https://www.youtube.com/watch?si=PWdwSScesAPsmeuo&v=jO4GXYcqZnQ&feature=youtu.be

hashtag hashtag hashtag hashtag

28/10/2025

🌸🎗 “I think those that would benefit most (from proton therapy) are left sided, medial tumors, and odd chest wall anatomy patients that can't lift their arms above their head […] and those that might have hearts that are close by their chest wall”

Continuing our Breast Cancer Awareness Month series, Dr. Shannon MacDonald, the clinical chair of RadComp and medical director of the Southwest Florida Proton Center, shares her perspective on which patients can benefit most from proton therapy in breast cancer treatment.

(S.M. MacDonald & Al. - Phase III randomized trial of proton vs. photon therapy for patients with non-metastatic breast cancer receiving comprehensive nodal radiation: A radiotherapy comparative effectiveness (RadComp) Consortium Trial: Health-related quality of life outcomes -ASTRO2025).

👉 Watch the full series on our YouTube channel to see how proton therapy is advancing breast cancer treatment: https://lnkd.in/eR-TXtkh

hashtag hashtag hashtag hashtag

22/10/2025

🌸🎗 “Our first outcome is health-related quality of life. We know that patient-reported outcomes and quality of life are extremely important. Our patients know more than we do about how they feel, and learning directly from them is often more meaningful.”

As we continue our series for the Breast Cancer Awareness Month, Dr. Shannon MacDonald, the clinical chair of RadComp and medical director of the Southwest Florida Proton Center, discusses the key outcomes studied in the RadComp breast cancer proton therapy trial focusing on quality of life and patient-reported experiences.

(S.M. MacDonald & Al. - Phase III randomized trial of proton vs. photon therapy for patients with non-metastatic breast cancer receiving comprehensive nodal radiation: A radiotherapy comparative effectiveness (RadComp) Consortium Trial: Health-related quality of life outcomes -ASTRO2025).

👉 Watch the full series on our YouTube channel to see how proton therapy is advancing breast cancer treatment: https://www.youtube.com/watch?si=LDma2jg2acd_ZuFG&v=tsyU-No-EM0&feature=youtu.be

21/10/2025

A must-attend event for the scientific community:

The latest results from a randomized multicenter Phase III study comparing Intensity-Modulated Proton Therapy (IMPT) with Intensity-Modulated Photon Therapy (IMRT) in the treatment of oropharyngeal carcinoma will be presented.

Special guest:
Steven J. Frank, Professor in the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center, Houston (Texas).

🗓️ November 13, 2025 | 12:00 – 14:00
📌 Starhotels Metropole, Via Principe Amedeo 3, Rome

Register here: https://form.jotform.com/252881701012347

20/10/2025

“The primary endpoint is to reduce major cardiac events. […] Major cardiac events are quite debilitating, life threatening and life altering.”

🌸🎗 As part of Breast Cancer Awareness Month, we continue our special video series with Dr. Shannon MacDonald, the clinical chair of RadComp and medical director of the Southwest Florida Proton Center, who shares the purpose behind the ongoing clinical trial studying proton therapy for breast cancer.

S.M. MacDonald & Al. - Phase III randomized trial of proton vs. photon therapy for patients with non-metastatic breast cancer receiving comprehensive nodal radiation: A radiotherapy comparative effectiveness (RadComp) Consortium Trial: Health-related quality of life outcomes - ASTRO2025).

👉 Watch the full series on our YouTube channel to see how proton therapy is advancing breast cancer treatment: youtube.com/watch?si=zJIkkM_yZKz5T5UR&v=z_f1AH59x-o&feature=youtu.be

17/10/2025

🌸🎗 “In the past, proton therapy had been used for partial breast irradiation. […] But no one had yet used it for locally advanced breast cancer, which was in my opinion, arguably a much better indication.”

As part of Breast Cancer Awareness Month, we are launching a special video series featuring Dr. Shannon MacDonald, the clinical chair of RadComp and medical director of the Southwest Florida Proton Center, who shares how her pioneering work with proton therapy has opened new possibilities in breast cancer treatment.

S.M. MacDonald & Al. - Phase III randomized trial of proton vs. photon therapy for patients with non-metastatic breast cancer receiving comprehensive nodal radiation: A radiotherapy comparative effectiveness (RadComp) Consortium Trial: Health-related quality of life outcomes - ASTRO2025).

👉 Watch the full series on our YouTube channel to see how proton therapy is advancing breast cancer treatment: https://www.youtube.com/watch?v=d5xWMSBDJh0

15/10/2025

𝗔𝗿𝗲 𝘆𝗼𝘂 𝗮𝗻 𝗜𝗕𝗔 𝗣𝗿𝗼𝘁𝗲𝘂𝘀 𝗨𝘀𝗲𝗿? Don’t miss the 𝗣𝗿𝗼𝘁𝗲𝘂𝘀 𝗨𝘀𝗲𝗿 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝟮𝟬𝟮𝟲 in Belgium!
Get ready for an unforgettable edition gathering the IBA Proteus Community.

📅 April 24–26, 2026
📍 Dolce La Hulpe Brussels

This exclusive event marks two major milestones:
🎉 25 years of patient treatments on Proteus - the first patient treated at Mass General Brigham
🎉 40 years of proton therapy innovation at IBA

Join us for a unique opportunity to collaborate, share knowledge, network, and engage in strategic discussions.

Watch Yves Jongen’s personal invitation below.

Spots are filling fast — register now!
👉 https://go.iba-worldwide.com/l/928513/2025-09-10/bkwkpw

29/09/2025

Excited to be at ASTRO 2025 in San Francisco!
Come visit us at booth #2013 to discover our latest innovations and enjoy a warm cup of coffee ☕.

📢 Don’t miss the insightful talk by Steven Frank on 𝗠𝗼𝗻𝗱𝗮𝘆 𝗮𝘁 𝟭𝟬:𝟭𝟱 𝗔𝗠, right at our booth for a talk about 𝗽𝗿𝗼𝘁𝗼𝗻 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗳𝗼𝗿 𝗵𝗲𝗮𝗱 𝗮𝗻𝗱 𝗻𝗲𝗰𝗸 𝗰𝗮𝗻𝗰𝗲𝗿.
Together, 𝗹𝗲𝘁’𝘀 𝗯𝗿𝗶𝗱𝗴𝗲 𝘁𝗵𝗲 𝗽𝗿𝗼𝘁𝗼𝗻 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗴𝗮𝗽 and advance cancer care through collaboration and innovation.

29/09/2025

Varian, a Siemens Healthineers company, and IBA Proton Therapy have entered into a Memorandum of Understanding to evaluate areas for strategic collaboration with the aim to strengthen interoperability and enhance clinical workflows in proton therapy, supporting our shared mission of improving access to care.

🌀 Eclipse and Proteus®ONE Compatibility – Varian’s Eclipse treatment planning system is now seamlessly compatible with IBA’s Proteus®ONE platform, enabling clinicians to streamline planning and delivery with optimized workflows.

🖼️ Launching DynamicARC® Planning in Eclipse – Both Varian and IBA are evaluating future possibilities for arc-based proton therapy planning in Eclipse. This collaboration aims to explore opportunities in treatment personalization and delivery efficiency, while continuing to advance current innovations across our platforms.

⚡Next-Generation Imaging in Proton Therapy – Together, IBA and Varian will explore co-developing advanced imaging solutions to enhance accuracy and confidence in patient positioning.

🧠 FLASH Therapy Quality Assurance – Joint efforts are underway to explore opportunities in quality assurance practices that may help enable future clinical implementation of FLASH therapy.

This developing collaboration underscores a shared commitment to expanding access, strengthening clinical workflows, and advancing intelligent cancer care. 🤝 Learn more at

* Flash therapy is under development and not available for sale. The products/features mentioned here are not commercially available in all countries. Their future availability cannot be guaranteed.
QR700029693

20/08/2025

We are proud to announce that we have signed a 𝗰𝗼𝗻𝘁𝗿𝗮𝗰𝘁 to install a 𝗣𝗿𝗼𝘁𝗲𝘂𝘀®𝗢𝗡𝗘 compact proton therapy solution to be located on the University campus in 𝗛𝗲𝗶𝗱𝗲𝗹𝗯𝗲𝗿𝗴, 𝗚𝗲𝗿𝗺𝗮𝗻𝘆.
The acquisition of this ProteusONE system marks a strategic expansion of Universitätsklinikum Heidelberg (UKHD)'s particle therapy program, which has been treating patients since 2010, ensuring continued access to cutting-edge, highly targeted treatment for patients with cancer using the latest techniques in proton therapy. This investment further strengthens UKHD’s role as a global reference center for precision radiation oncology, combining scientific excellence with patient-centered innovation.

👉 Read the full press release here: https://www.iba-worldwide.com/heidelberg-university-hospital-expands-its-particle-therapy-program-ibas-proteusrone-solution

15/07/2025

Have you heard of proton therapy, but are not quite sure how it works?

Our short and simple video explains everything!

Watch it here and share with someone who might find it helpful 👇

Adres

Chemin Du Cyclotron 3
Louvain-la-Neuve
1348

Website

http://www.iba-protontherapy.com/why-iba

Meldingen

Wees de eerste die het weet en laat ons u een e-mail sturen wanneer IBA Proton Therapy nieuws en promoties plaatst. Uw e-mailadres wordt niet voor andere doeleinden gebruikt en u kunt zich op elk gewenst moment afmelden.